Adamas pharmaceuticals inc (ADMS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities
Net loss

-105,186

-130,999

-89,490

-60,058

-51,802

10,223

50,921

17,736

Adjustments to reconcile net loss to net cash used in operating activities
Depreciation

1,200

1,500

1,200

800

435

155

66

41

Stock-based compensation

12,852

15,786

13,367

10,571

9,956

7,203

640

797

Provision for employee notes receivable

-

-

-

-

-

-

-

158

Accretion of interest expense

15,044

19,092

4,645

0

0

-

-

377

Change in fair value of embedded derivative liability

-805

-882

294

0

0

-

-

-

Change in preferred stock warrant value

-

-

-

-

-

983

4,526

1,330

Net accretion of discounts and amortization of premiums of available-for-sale securities

1,219

1,045

-456

301

-875

1,361

-

-

Loss on disposal of fixed assets

0

-123

0

0

-

-

-

-

Provision for write-down of inventory

900

200

0

0

-

-

-

-

Issuance of common stock and vesting of restricted common stock for services rendered

-

-

-

-

-

-

52

67

Loss on fixed asset disposal

-

-

-

-

-

-111

-

-

Changes in assets and liabilities
Accrued interest of available-for-sale securities

-50

-74

161

2

-110

0

-

-

Accounts receivable, net

259

5,144

-427

-490

760

395

-761

516

Inventory

970

3,273

1,646

0

0

-

-

-

Prepaid expenses and other assets

-1,560

5,036

2,036

-2,643

4,416

381

-80

39

Operating lease right-of-use assets

-1,008

-

-

-

-

-

-

-

Accounts payable

398

2,759

333

-

-

-

-

-

Accounts payable

-

-

-

502

-788

1,521

-1,157

1,799

Current portion of long-term debt

-6,450

-2,618

0

-

-

-

-

-

Long-term portion of operating lease liabilities

1,188

0

0

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-29,611

29,611

Accrued liabilities and other liabilities

678

3,484

6,378

-2,721

-820

9,734

523

600

Net cash used in operating activities

-80,779

-104,223

-66,827

-48,068

-47,210

27,793

-

-

Net cash used in operating activities

-

-

-

-

-

-

26,801

51,961

Cash flows from investing activities
Purchases of property and equipment

18

1,064

1,258

1,624

1,399

1,285

167

24

Purchases of available-for-sale securities

93,869

200,354

62,510

103,528

59,828

96,095

-

-

Maturities of available-for-sale securities

182,750

132,080

89,333

78,443

69,285

0

-

-

Net cash provided by (used in) investing activities

88,863

-69,338

25,565

-26,709

8,058

-97,380

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-167

-24

Cash flows from financing activities
Proceeds from public offerings, net of offering costs

0

134,268

0

61,822

9,657

42,632

-

-

Proceeds from issuance of long-term debt

0

0

99,600

0

0

-

-

-

Payment of debt issuance costs

0

0

633

0

0

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

3,948

Proceeds from issuance of common stock upon exercise of stock options

310

3,345

9,110

2,966

-

-

21

7

Proceeds from employee stock purchase plan

775

1,237

766

620

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options

-

-

-

-

746

1,011

-

-

Proceeds from issuance of convertible promissory notes and related warrants

-

-

-

-

-

-

-

3,948

Proceeds from employee stock purchase plan

-

-

-

-

407

162

-

-

Principal payments on convertible promissory notes

-

-

-

-

-

-

4,000

-

Repurchase of common stock

-

-

-

-

-

370

-

-

Proceeds from issuance of common and preferred stock upon exercise of warrants

-

-

-

-

-

1,986

-

-

Net cash provided by financing activities

1,085

138,850

108,843

65,408

10,810

45,421

-

-

Net increase (decrease) in cash and cash equivalents

9,169

-34,711

67,581

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-9,369

-28,342

-24,166

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-3,979

7,903

Net decrease in cash and cash equivalents

-

-

-

-

-

-

22,655

59,840

Supplemental disclosure
Cash paid for interest

6,450

2,618

0

0

-

-

-

-

Cash paid for income taxes

-

-

-

-

4,691

341

1,417

-

Cash paid for interest

-

-

-

-

-

-

279

-

Supplemental disclosure of noncash activities
Right-of-use assets obtained in exchange for operating lease liabilities

9,056

-

-

-

-

-

-

-

Property and equipment in accounts payable and accrued expense

0

7

61

148

161

0

-

-

Stock-based compensation capitalized in inventory

208

202

39

0

0

-

-

-

Stock option exercise settled after period end

0

17

0

76

0

0

-

-

Property and equipment acquired through tenant improvement allowance

0

1,129

0

0

-

-

-

-